Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ligand Pharm (LGND)

Ligand Pharm (LGND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,815,311
  • Shares Outstanding, K 17,563
  • Annual Sales, $ 120,280 K
  • Annual Income, $ 629,300 K
  • 60-Month Beta 1.32
  • Price/Sales 14.98
  • Price/Cash Flow 30.80
  • Price/Book 2.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 0.32
  • Number of Estimates 1
  • High Estimate 0.32
  • Low Estimate 0.32
  • Prior Year 0.97
  • Growth Rate Est. (year over year) -67.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
87.46 +12.74%
on 01/29/20
122.08 -19.23%
on 02/27/20
+10.58 (+12.02%)
since 01/28/20
3-Month
85.70 +15.05%
on 01/27/20
122.08 -19.23%
on 02/27/20
-14.27 (-12.64%)
since 11/27/19
52-Week
84.45 +16.76%
on 09/10/19
130.50 -24.44%
on 04/12/19
-25.48 (-20.54%)
since 02/28/19

Most Recent Stories

More News
Ligand Raises 2020 Financial Guidance Due to Higher Captisol Material Sales

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces an update to its financial outlook and raises its 2020 financial guidance. Ligand now expects 2020 total revenues to be approximately $133 million...

LGND : 95.45 (-7.65%)
INVESTOR ALERT: BDX LGND LOPE SBT: Kirby McInerney LLP Continues Investigation of Shareholder Claims

The law firm of Kirby McInerney LLP is investigating whether the following publicly-traded companies have violated federal securities laws and/or engaged in other unlawful business practices.

BDX : 233.83 (-3.65%)
LGND : 95.45 (-7.65%)
LOPE : 80.80 (-1.39%)
SBT : 7.08 (-0.28%)
Ligand Agrees to Acquire Core Assets, Partnered Programs and Ion Channel Technologies from Icagen

--Slides to accompany this announcement are posted to Ligand.com

LGND : 95.45 (-7.65%)
Look for Shares of Ligand Pharm to Potentially Pullback after Yesterday's 5.70% Rise

Ligand Pharm (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $92.50 to a high of $98.86. Yesterday, the shares gained 5.7%, which took the trading range above the 3-day high of $94.78...

LGND : 95.45 (-7.65%)
Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up

Ligand (LGND) reports higher-than-expected fourth-quarter 2019 earnings and revenues.

NVS : 83.32 (-3.14%)
LGND : 95.45 (-7.65%)
AMGN : 197.21 (-3.09%)
CASI : 1.86 (-0.53%)
Ligand Pharmaceuticals (LGND) Surpasses Q4 Earnings and Revenue Estimates

Ligand (LGND) delivered earnings and revenue surprises of 4.41% and 8.27%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

LGND : 95.45 (-7.65%)
Ligand: 4Q Earnings Snapshot

SAN DIEGO (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Thursday reported a fourth-quarter loss of $7.4 million, after reporting a profit in the same period a year earlier.

LGND : 95.45 (-7.65%)
Ligand Reports Fourth Quarter and Full Year 2019 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2019, and provided an operating forecast and program updates. Ligand management...

LGND : 95.45 (-7.65%)
Ligand Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 6, 2020 / Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 6,...

LGND : 95.45 (-7.65%)
12.0% Return Seen to Date on SmarTrend Ligand Pharm Call (LGND)

SmarTrend identified a Downtrend for Ligand Pharm (NASDAQ:LGND) on December 5th, 2019 at $106.45. In approximately 2 months, Ligand Pharm has returned 11.98% as of today's recent price of $93.69.

LGND : 95.45 (-7.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade LGND with:

Business Summary

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases....

See More

Key Turning Points

2nd Resistance Point 128.47
1st Resistance Point 115.92
Last Price 95.45
1st Support Level 96.97
2nd Support Level 90.57

See More

52-Week High 130.50
Fibonacci 61.8% 112.91
Fibonacci 50% 107.47
Fibonacci 38.2% 102.04
Last Price 95.45
52-Week Low 84.45

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar